Myriad Genetics (MYGN) Tops Q3 EPS by 8c
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $5.87 -3.77%
EPS Growth %: -220.0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -220.0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.06), $0.08 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $173.1 million versus the consensus estimate of $156.2 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- What Delta’s report tells investors in American and United
- Cohu (COHU) PT Raised to $70 at Stifel on Expectation of 'More Buoyant Multiple'
- UBS Reiterates Neutral Rating on Buckle, Inc. (BKE)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
